Expression of cyclin-dependent kinase 9 is positively correlated with the autophagy level in colon cancer

Table 2 Basic information of patients expressing ABCG2, n (%)

Characteristic	Category	Low expression of ABCG2, n = 322	High expression of ABCG2, n = 322	P value
T stage	T1	15 (2.3)	5 (0.8)	0.114
	T2	54 (8.4)	57 (8.9)
	T3	219 (34.2)	217 (33.9)
	T4	33 (5.1)	41 (6.4)
N stage	N0	209 (32.7)	159 (24.8)	< 0.001
	N1	76 (11.9)	77 (12.0)
	N2	36 (5.6)	83 (13.0)
M stage	M0	239 (42.4)	236 (41.8)	0.111
	M1	36 (6.4)	53 (9.4)
Primary therapy outcome	PD	12 (3.8)	21 (6.7)	0.305
	SD	2 (0.6)	3 (1.0)
	PR	10 (3.2)	6 (1.9)
	CR	129 (41.3)	129 (41.3)
Sex	Female	143 (22.2)	158 (24.5)	0.269
	Male	179 (27.8)	164 (25.5)
CEA level	≤ 5	127 (30.6)	134 (32.3)	0.986
	> 5	74 (17.8)	80 (19.3)
Perineural invasion	No	90 (38.3)	85 (36.2)	0.351
	Yes	26 (11.1)	34 (14.5)
Lymphatic invasion	No	192 (33.0)	158 (27.1)	0.007
	Yes	100 (17.2)	132 (22.7)
History of colon polyps	No	182 (32.8)	195 (35.1)	0.510
	Yes	92 (16.6)	86 (15.5)
Neoplasm type	Colon adenocarcinoma	244 (37.9)	234 (36.3)	0.417
	Rectum adenocarcinoma	78 (12.1)	88 (13.7)
Age in yr, median (IQR)		68.0 (59.0, 75.8)	68.0 (57.3, 76.0)	0.423

CDK9: Cyclin-dependent kinase 9; CEA: Carcinoembryonic antigen; PD: Progressive disease; PR: Partial response; SD: Stable disease; CR: Complete response; IQR: Interquartile range.